Verseon

Verseon Verseon’s breakthroughs in molecular physics, AI, and biological characterization create truly novel pharmaceuticals.

Atom by atom, we drive innovation, change lives, and revolutionize the standard of care. Verseon develops novel drugs with unique properties using a proprietary physics and AI-driven platform. Verseon is addressing the cycle of slow and derivative pharmaceutical drug discovery by systematically creating truly novel molecular entities. We innovate beyond the bounds of the known chemical space. We d

esign, test, and synthesize never-been-seen molecules atom by atom that may soon become life-changing drugs. We began our mission in 2002 and since have created our proprietary platform based on fundamental scientific advances built in-house. We are currently a clinical-stage company making great strides in cardiovascular disease, diabetic retinopathy, cancer, and liver disease with over a dozen drug candidates in active development. Our mission is to change the standard of care for every disease we address.

The European Patent Office recently granted patent protection for our plasma (PK) inhibitors. PK is a validated targ...
09/15/2022

The European Patent Office recently granted patent protection for our plasma (PK) inhibitors. PK is a validated target in diabetic (DR) and diabetic macular edema (DME), chronic diseases that lead to a form of vision loss associated with . Inhibiting PK also holds promise as a treatment for hereditary angioedema ( ), a potentially fatal condition characterized by severe swelling.

Covered compounds could provide revolutionary oral treatments for several chronic and fatal conditions

“Verseon...is fishing...in the largely uncharted ocean of chemical space, using molecular physics to accurately predict ...
05/06/2022

“Verseon...is fishing...in the largely uncharted ocean of chemical space, using molecular physics to accurately predict how new chemical structures will bind to particular proteins.”


BioSpace

"What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules."

“Integrating AI and molecular modeling is likely to produce far more powerful breakthroughs in small molecule drug disco...
05/03/2022

“Integrating AI and molecular modeling is likely to produce far more powerful breakthroughs in small molecule drug discovery than either approach could individually.”


"AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."

"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first ...
04/22/2022

"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."

Impact Wealth Magazine

"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."

“We’ve spent a decade and a half developing fundamental advancements in computational chemistry, molecular-physics model...
04/19/2022

“We’ve spent a decade and a half developing fundamental advancements in computational chemistry, molecular-physics modeling, and applications of AI to make systematic design of completely new drug molecules a reality.”



https://bit.ly/3OvqYgr

MarkTechPost Features Verseon’s CEO in AI in Healthcare Issue "… our ability to explore uncharted chemical space allows us to find drug candidates with uniquely desirable properties for the treatment of every disease we address."

Address

48383 Fremont Boulevard , Suite 122
Fremont, CA
94538

Website

Alerts

Be the first to know and let us send you an email when Verseon posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Verseon:

Shortcuts

Share

Category